PhosChol (Phosphatidylcholine)

PhosChol is a highly purified phosphatidylcholine (PC) concentrate derived from soy lecithin, providing the bioactive phospholipid that forms the structural backbone of cell membranes and bile. It supports liver and gut health primarily by restoring phospholipid composition in hepatocyte membranes and reinforcing the intestinal mucus layer via PC-enriched mucus secretion.

Origin & History

PhosChol is a branded form of phosphatidylcholine (PC), a phospholipid extracted from soy lecithin through solvent fractionation or chromatography to enrich for polyunsaturated PC species. It consists of a glycerol backbone esterified with two fatty acids and a phosphocholine headgroup, sourced from soybeans (Glycine max).

Historical & Cultural Context

No traditional medicine use was documented in the research. Modern therapeutic applications emerged post-2000s, derived from lecithin research since the mid-20th century for liver support, without specific ties to traditional medicine systems.

Health Benefits

• Ulcerative colitis support: Phase 2 RCT showed 50% of patients achieved steroid withdrawal vs 10% placebo (moderate evidence)
• Liver health in NAFLD: Observational study of 2,843 patients showed 68.3% improved liver echogenicity at 24 weeks (preliminary evidence)
• Gut barrier protection: May strengthen mucosal barrier by integrating into mucus phospholipids (preliminary evidence)
• Steroid-sparing effect: 80% of UC patients discontinued steroids without flare vs 10% placebo in one trial (moderate evidence)
• Hepatocyte protection: Polish RCT showed 26.7% histological improvement in NAFLD patients vs 7.1% placebo (preliminary evidence)

How It Works

Phosphatidylcholine is incorporated into hepatocyte plasma membranes via the CDP-choline (Kennedy) pathway, restoring membrane fluidity and reducing lipid peroxidation by serving as a substrate for phospholipase A2-mediated arachidonic acid release modulation. In the intestinal tract, PC is secreted into the mucus gel layer by goblet cells, where it forms a hydrophobic barrier that limits bacterial translocation and reduces NFκB-driven mucosal inflammation. PC also donates choline for betaine synthesis via choline oxidase, supporting hepatic methionine metabolism and SAM-dependent methylation reactions critical for VLDL assembly and fat export from the liver.

Scientific Research

Key trials include a phase 2 RCT (PMID: 17975182) showing efficacy in 60 steroid-refractory UC patients, though a larger phase 3 trial (PMID: 37806372) was terminated early for futility. A large observational study (PMC7011021) in 2,843 NAFLD patients demonstrated improvements in liver echogenicity, supported by smaller RCTs showing histological benefits.

Clinical Summary

A Phase 2 randomized controlled trial in ulcerative colitis patients demonstrated that delayed-release phosphatidylcholine achieved steroid withdrawal in 50% of participants versus 10% in the placebo group, representing moderate-quality evidence. A large observational study of 2,843 NAFLD patients treated with polyenylphosphatidylcholine reported improved liver echogenicity (a sonographic marker of hepatic fat) in 68.3% of subjects at 24 weeks, though the absence of randomization limits causal inference. Preclinical and early human data suggest PC supplementation strengthens gut barrier function by enriching the colonic mucus phospholipid content, reducing bacterial endotoxin translocation, but large RCTs in this application are lacking. Overall, evidence is strongest for ulcerative colitis and promising but preliminary for NAFLD and gut permeability.

Nutritional Profile

PhosChol is a highly purified phosphatidylcholine (PC) concentrate derived from soy lecithin, standardized to contain approximately 900mg of polyenylphosphatidylcholine (PPC) per softgel (standard dose). Primary bioactive compound: phosphatidylcholine (≥99% purity in PhosChol Concentrate), composed of glycerophosphocholine backbone esterified with predominantly polyunsaturated fatty acids — linoleic acid (omega-6, ~50-60% of fatty acid composition) and other polyunsaturated fatty acids. Choline content: approximately 250-400mg elemental choline equivalent per 900mg PC dose, contributing to dietary choline intake (AI: 425-550mg/day for adults). Lipid composition: phospholipid class constitutes ~100% of active fraction, with negligible triglycerides, cholesterol, or other lipid fractions due to purification process. No significant protein, carbohydrate, or dietary fiber content. Micronutrients: trace amounts only — not a meaningful source of vitamins or minerals. Bioavailability notes: phosphatidylcholine is hydrolyzed in the small intestine by phospholipase A2 to lysophosphatidylcholine (LPC), which is the primary absorbed form via intestinal epithelial cells; LPC is re-acylated back to PC in enterocytes and incorporated into chylomicrons for lymphatic transport. A portion of choline moiety is metabolized by gut microbiota to trimethylamine (TMA), subsequently oxidized to TMAO in the liver — relevant for cardiovascular considerations. The polyunsaturated fatty acid profile distinguishes PPC from saturated PC forms, conferring membrane-fluidizing properties and mucosal integration capacity. Caloric contribution: approximately 8-10 kcal per 900mg softgel (primarily from fatty acid chains).

Preparation & Dosage

Ulcerative colitis: 2-3.2 g/day (divided into 4 doses). NAFLD/NASH: 1.368-2.1 g/day (typically 600-700 mg three times daily). Forms include standard PC powder and delayed-release formulations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Milk thistle, Alpha-lipoic acid, N-acetylcysteine, Vitamin E, Curcumin

Safety & Interactions

PhosChol is generally well tolerated at typical doses of 900–1,800 mg PC daily; the most common side effects are mild gastrointestinal complaints including nausea, loose stools, and increased salivation, which are dose-dependent. Gut microbiota (specifically TMA lyase-expressing bacteria) can metabolize the choline moiety of PC to trimethylamine (TMA), which is hepatically oxidized to TMAO, a compound associated with cardiovascular risk at chronically elevated levels — a consideration for individuals with dysbiosis or high cardiovascular baseline risk. PC may theoretically potentiate cholinergic drugs (e.g., acetylcholinesterase inhibitors such as donepezil) by increasing acetylcholine substrate availability, warranting caution in patients on these medications. Safety data in pregnancy are limited; while dietary choline is essential during pregnancy, supplemental high-dose PC should only be used under medical supervision in pregnant or breastfeeding individuals.